MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Search

Grifols SA

Avatud

SektorRahandus

8.55 1.54

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.374

Max

8.538

Põhinäitajad

By Trading Economics

Sissetulek

17M

69M

Müük

183M

2B

P/E

Sektori keskmine

36.313

20.525

Aktsiakasum

0.101

Kasumimarginaal

3.491

Töötajad

23,833

EBITDA

57M

482M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+65.92% upside

Turustatistika

By TradingEconomics

Turukapital

1.6B

5.2B

Eelmine avamishind

7.01

Eelmine sulgemishind

8.55

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Grifols SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2025, 17:19 UTC

Omandamised, ülevõtmised, äriostud

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2. apr 2025, 13:02 UTC

Omandamised, ülevõtmised, äriostud

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2. apr 2025, 10:13 UTC

Omandamised, ülevõtmised, äriostud

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8. juuli 2024, 10:40 UTC

Omandamised, ülevõtmised, äriostud

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8. juuli 2024, 09:13 UTC

Omandamised, ülevõtmised, äriostud

Grifols Faces Delisting Bid From Founding Family and Brookfield

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2. apr 2025, 09:27 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Võrdlus sarnastega

Hinnamuutus

Grifols SA Prognoos

Hinnasiht

By TipRanks

65.92% tõus

12 kuu keskmine prognoos

Keskmine 14.02 EUR  65.92%

Kõrge 19.05 EUR

Madal 11 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Grifols SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

8.006 / 8.544Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.